Please use this identifier to cite or link to this item:
|Title:||HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review)|
Ko Ichi Kawahara
Yame General Hospital
Kurume University School of Medicine
Kagoshima University Faculty of Medicine
Nishida Koutoku Hospital
Kohjin Co., Ltd.
Saiseikai Shiga Hospital
Omuta City General Hospital
Osaka Institute of Technology
|Keywords:||Biochemistry, Genetics and Molecular Biology;Immunology and Microbiology|
|Citation:||Experimental and Therapeutic Medicine. Vol.2, No.5 (2011), 767-770|
|Abstract:||Historically, clinical outcomes following spinal cord injury (SCI) have been dismal. Severe SCI leads to devastating neurological deficits, and there is no treatment available that restores the injury-induced loss of function to a degree that an independent life can be guaranteed. To address all the issues associated with SCI, a multidisciplinary approach is required, as it is unlikely that a single approach, such as surgical intervention, pharmacotherapy or cellular transplantation, will suffice. High mobility group box 1 (HMGB1) is an inflammatory cytokine. Various studies have shown that HMGB1 plays a critical role in SCI and that inhibition of HMGB1 release may be a novel therapeutic target for SCI and may support spinal cord repair. In addition, HMGB1 has been associated with graft rejection in the early phase. Therefore, HMGB1 may be a promising therapeutic target for SCI transplant.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.